Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301
The primary objective of the study is to assess the safety and tolerability of long-term treatment with DAC HYP monotherapy in subjects who completed Study 205MS301, Study 205MS203, or Study 205MS302
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS. The number and percentage of subjects who develop neutralizing antibodies (NAbs) ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Open-Label, Multicenter, Phase 2/3 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia
To determine the effectiveness of lumiliximab when used in combination with Fludarabine, Cyclophosfamide and Rituximab (FCR) compared with Fludarabine, Cyclophosphamide and Rituximab (FCR) alone for t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Biogen Idec Hemophilia Inc
Update Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds
• To evaluate the safety and tolerability of rFVIIIFc administered as a prophylaxis, weekly, on-demand, and surgical treatment regimen • To evaluate the efficacy of the rFVIIIFc tailored prophylaxis ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
TYSABRI Long Term Re-Dosing Study
Initial Treatment Period: To further evaluate the safety of natalizumab monotherapy by: 1) evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab and 2) co...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
Estudio aleatorizado de interrrupción de tratamiento con Natalizumab" "Randomized Treatment Interruption of Natalizumab
1.Cómo evoluciona la recuperación de la función inmunitaria, utilizando los marcadores indirectos 2. Cómo evoluciona la reaparición de pruebas radiológicas y/o clínicas de actividad de la EM 3. El ef...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how two different strengths of an experimental replacement factor VIII protein (known as rFVIIIFc) are processed by the body and how safe it is to take
The primary objective of the study is to characterize the PK of rFVIIIFc administered at vial strengths of 1000 and 3000 IU in subjects with severe hemophilia A.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Biogen Idec
Update Il y a 4 ans
BIOGEN IDEC 114-NH-301 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité du rituximab associé ou non à du galiximab, chez des patients ayant un lymphome folliculaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase III, randomized, double-blind study of galiximab in combination with rituximab compared with rituximab in combination with placebo for the treatment of subjects with relapsed or refractory, fo...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec
Update Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency
The primary objective of this study is to assess the safety and tolerability of Tonapofylline administered to subjects with heart failure and renal insufficiency
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
Next